Combination therapy for advanced neuroendocrine cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a rare type of cancer called large cell neuroendocrine carcinoma (LCNEC) or extra-pulmonary neuroendocrine carcinoma (EP-NEC) that has spread (metastasized).
- You have not had any chemotherapy or other cancer treatment for the metastatic cancer. If you had earlier treatment for non-spread cancer, it must have finished at least 6 months before this cancer was found.
- You are between 18 and 75 years old and your general health is reasonably good (able to do light work or be fully active).
- Your cancer can be measured on a scan (like CT or MRI). If a previously treated spot is used, it must have clearly grown.
- Your blood counts, liver, kidney, and heart function must be within certain limits, and you must be willing to use effective birth control during and for 6 months after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug (LBL-024) combined with standard chemotherapy for people with advanced EP-NEC, a rare type of neuroendocrine tumor. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and chemotherapy for people with neuroendocrine carcinoma that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Large Cell Neuroendocrine Carcinoma of the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.